Heabah, N., Bedeer, A. (2021). Assessment of PD-L1 and p53 expression in urinary bladder carcinoma: Association with different clinicopathologic characteristics. International Journal of Cancer and Biomedical Research, 5(1), 15-26. doi: 10.21608/jcbr.2020.35710.1054
Nehal A. Heabah; Asmaa E. Bedeer. "Assessment of PD-L1 and p53 expression in urinary bladder carcinoma: Association with different clinicopathologic characteristics". International Journal of Cancer and Biomedical Research, 5, 1, 2021, 15-26. doi: 10.21608/jcbr.2020.35710.1054
Heabah, N., Bedeer, A. (2021). 'Assessment of PD-L1 and p53 expression in urinary bladder carcinoma: Association with different clinicopathologic characteristics', International Journal of Cancer and Biomedical Research, 5(1), pp. 15-26. doi: 10.21608/jcbr.2020.35710.1054
Heabah, N., Bedeer, A. Assessment of PD-L1 and p53 expression in urinary bladder carcinoma: Association with different clinicopathologic characteristics. International Journal of Cancer and Biomedical Research, 2021; 5(1): 15-26. doi: 10.21608/jcbr.2020.35710.1054
Assessment of PD-L1 and p53 expression in urinary bladder carcinoma: Association with different clinicopathologic characteristics
Pathology Department, Faculty of Medicine, Tanta University, Tanta, Egypt
Abstract
Background: Urinary bladder carcinoma is the most common urologic malignancy that includes phenotypically and genotypically diverse tumors. The development of new treatment modalities is essential to improve the outcomes and increase the overall survival of urinary bladder carcinoma patients’. Among these modalities, comes the PD-L1 inhibitors, as promising immunotherapy. P53 may also play a role in these treatment strategies. Aim: This study aimed to evaluate PD-L1 and p53 expression in urinary bladder carcinoma, and its available variants, and relate PD-L1 and p53 expression to each other and the available clinicopathological features. Materials and methods: This study included 60 cases of urinary bladder carcinoma, with no history of radiotherapy or chemotherapy, classified as follows: 32 cases of urothelial carcinoma, 25 squamous cell carcinomas, and 3 adenocarcinomas. Immunohistochemical staining of all cases using PD-L1 and p53 was done. Results: Positive PD-L1 expression was detected in 51.7% of all cases. PD-L1 expression was significantly associated with the histopathological types, high tumor grade and muscle invasion. High p53 expression was detected in 50% of the studied cases. P53 expression was significantly associated with high tumor grade, advanced stage, vascular invasion and lymph node metastasis. PD-L1 and p53 co-expression was detected in 33.3% of the cases. PD-L1 positivity was significantly associated with p53 expression. Conclusions: PD-L1 and p53 could be considered as predicting biomarkers for aggressive bladder carcinoma and their immunohistochemical expression may aid in identifying suitable patients for target therapy.
Top